Aethlon Medical reports positive in vitro Hemopurifier data for removing extracellular vesicles from cancer plasma

AETHLON MEDICAL INC

In vitro binding study of Hemopurifier shows removal of extracellular vesicles (EVs) directly from cancer patient plasma.
Data supports planned Phase 1 trial in solid tumor patients on anti-PD-1 therapies (Keytruda/Opdivo).
Descriptive statistics from CRO NAMSA confirm EV removal; PD-L1+ EV subset inconclusive due to low counts.
Next step: submit data to Ethics Committees in Australia and India to initiate Phase 1 oncology studies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.